282 related articles for article (PubMed ID: 25848912)
1. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study.
Peeters SA; Engelen L; Buijs J; Chaturvedi N; Fuller JH; Schalkwijk CG; Stehouwer CD;
Cardiovasc Diabetol; 2015 Mar; 14():31. PubMed ID: 25848912
[TBL] [Abstract][Full Text] [Related]
2. Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies.
Peeters SA; Engelen L; Buijs J; Chaturvedi N; Fuller JH; Jorsal A; Parving HH; Tarnow L; Theilade S; Rossing P; Schalkwijk CG; Stehouwer CDA
Cardiovasc Diabetol; 2017 Oct; 16(1):139. PubMed ID: 29070037
[TBL] [Abstract][Full Text] [Related]
3. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.
Peeters SA; Engelen L; Buijs J; Jorsal A; Parving HH; Tarnow L; Rossing P; Schalkwijk CG; Stehouwer CDA
Cardiovasc Diabetol; 2017 Apr; 16(1):55. PubMed ID: 28446168
[TBL] [Abstract][Full Text] [Related]
4. Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study.
Nin JW; Ferreira I; Schalkwijk CG; Prins MH; Chaturvedi N; Fuller JH; Stehouwer CD;
Eur J Endocrinol; 2012 Feb; 166(2):325-32. PubMed ID: 22127490
[TBL] [Abstract][Full Text] [Related]
5. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
6. Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes.
Peeters SA; Engelen L; Buijs J; Theilade S; Rossing P; Schalkwijk CG; Stehouwer CDA
J Diabetes Complications; 2018 Mar; 32(3):325-329. PubMed ID: 29395841
[TBL] [Abstract][Full Text] [Related]
7. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy.
Jacqueminet S; Ben Abdesselam O; Chapman MJ; Nicolay N; Foglietti MJ; Grimaldi A; Beaudeux JL
Clin Chim Acta; 2006 May; 367(1-2):103-7. PubMed ID: 16426593
[TBL] [Abstract][Full Text] [Related]
8. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
[TBL] [Abstract][Full Text] [Related]
9. Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level.
Komosinska-Vassev K; Olczyk P; Winsz-Szczotka K; Kuznik-Trocha K; Klimek K; Olczyk K
Gerontology; 2011; 57(1):44-52. PubMed ID: 20215736
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes.
Maxwell PR; Timms PM; Chandran S; Gordon D
Diabet Med; 2001 Oct; 18(10):777-80. PubMed ID: 11678966
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.
Lorente L; Martín MM; Labarta L; Díaz C; Solé-Violán J; Blanquer J; Orbe J; Rodríguez JA; Jiménez A; Borreguero-León JM; Belmonte F; Medina JC; Llimiñana MC; Ferrer-Agüero JM; Ferreres J; Mora ML; Lubillo S; Sánchez M; Barrios Y; Sierra A; Páramo JA
Crit Care; 2009; 13(5):R158. PubMed ID: 19799791
[TBL] [Abstract][Full Text] [Related]
12. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
14. Serum tissue-degrading proteinases and incident cardiovascular disease events.
Tuomainen AM; Kormi I; Havulinna AS; Tervahartiala T; Salomaa V; Sorsa T; Pussinen PJ
Eur J Prev Cardiol; 2014 Jul; 21(7):806-12. PubMed ID: 23079500
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases during and outside of migraine attacks without aura.
Ashina M; Tvedskov JF; Lipka K; Bilello J; Penkowa M; Olesen J
Cephalalgia; 2010 Mar; 30(3):303-10. PubMed ID: 19614693
[TBL] [Abstract][Full Text] [Related]
16. Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta.
Kuźnik-Trocha K; Winsz-Szczotka K; Komosińska-Vassev K; Jura-Półtorak A; Kotulska-Kucharz A; Kucharz EJ; Kotyla P; Olczyk K
Biomed Res Int; 2020; 2020():6416514. PubMed ID: 32382564
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus.
Papazafiropoulou A; Perrea D; Moyssakis I; Kokkinos A; Katsilambros N; Tentolouris N
J Diabetes Complications; 2010; 24(1):20-7. PubMed ID: 19062310
[TBL] [Abstract][Full Text] [Related]
18. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation.
Kalogeropoulos AS; Tsiodras S; Rigopoulos AG; Sakadakis EA; Triantafyllis A; Kremastinos DT; Rizos I
BMC Cardiovasc Disord; 2011 Dec; 11():77. PubMed ID: 22204652
[TBL] [Abstract][Full Text] [Related]
19. Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis.
Jones TK; Reilly JP; Anderson BJ; Miano TA; Dunn TG; Weisman AR; Agyekum R; Feng R; Ittner CAG; Shashaty MGS; Meyer NJ
Shock; 2022 Jan; 57(1):41-47. PubMed ID: 34265829
[TBL] [Abstract][Full Text] [Related]
20. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
